These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1. Sippel TR; Johnson AM; Li HY; Hanson D; Nguyen TT; Bullock BL; Poczobutt JM; Kwak JW; Kleczko EK; Weiser-Evans MC; Nemenoff RA Mol Cancer Res; 2019 Aug; 17(8):1748-1758. PubMed ID: 31088909 [TBL] [Abstract][Full Text] [Related]
8. Inflammation as a driver and vulnerability of KRAS mediated oncogenesis. Kitajima S; Thummalapalli R; Barbie DA Semin Cell Dev Biol; 2016 Oct; 58():127-35. PubMed ID: 27297136 [TBL] [Abstract][Full Text] [Related]
9. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Parente P; Parcesepe P; Covelli C; Olivieri N; Remo A; Pancione M; Latiano TP; Graziano P; Maiello E; Giordano G Gastroenterol Res Pract; 2018; 2018():7530619. PubMed ID: 30662458 [TBL] [Abstract][Full Text] [Related]
10. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. Chu PC; Yang MC; Kulp SK; Salunke SB; Himmel LE; Fang CS; Jadhav AM; Shan YS; Lee CT; Lai MD; Shirley LA; Bekaii-Saab T; Chen CS Oncogene; 2016 Jul; 35(30):3897-908. PubMed ID: 26616862 [TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. Wood K; Hensing T; Malik R; Salgia R JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819 [TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440 [TBL] [Abstract][Full Text] [Related]
14. Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Wang ZD; Wei SQ; Wang QY Am J Cancer Res; 2015; 5(11):3339-49. PubMed ID: 26807315 [TBL] [Abstract][Full Text] [Related]
16. Epiregulin as a therapeutic target in non-small-cell lung cancer. Sunaga N; Kaira K Lung Cancer (Auckl); 2015; 6():91-98. PubMed ID: 28210154 [TBL] [Abstract][Full Text] [Related]
17. Challenges in Ras therapeutics in pancreatic cancer. Choi M; Bien H; Mofunanya A; Powers S Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065 [TBL] [Abstract][Full Text] [Related]
18. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. Wang K; Baldwin GS; Nikfarjam M; He H World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477 [TBL] [Abstract][Full Text] [Related]
19. The Emerging Role of the Microenvironment in Endometrial Cancer. Sahoo SS; Zhang XD; Hondermarck H; Tanwar PS Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30380719 [TBL] [Abstract][Full Text] [Related]
20. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]